Biogen price target lowered to $163 from $178 at BofA
BofA lowered the firm’s price target on Biogen (BIIB) to $163 from $178 and keeps a Neutral rating on the shares. The firm calls Biogen “one of ...
Biogen initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...